<div id=toc></div>

# Table of Contents

- [q-bio.BM](#q-bio.BM) [Total: 3]
- [cs.AI](#cs.AI) [Total: 2]
- [cs.LG](#cs.LG) [Total: 2]


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [1] [IntFold: A Controllable Foundation Model for General and Specialized Biomolecular Structure Prediction](https://arxiv.org/abs/2507.02025)
*The IntFold Team,Leon Qiao,Wayne Bai,He Yan,Gary Liu,Nova Xi,Xiang Zhang*

Main category: q-bio.BM

TL;DR: IntFold是一个可控的生物分子结构预测基础模型，其预测精度与最先进的AlphaFold3相当，但采用了更优的自定义注意力核。


<details>
  <summary>Details</summary>
Motivation: 旨在开发一个既能用于通用又能用于专业生物分子结构预测的模型，同时扩展其功能以预测变构状态、约束结构和结合亲和力。

Method: 采用自定义注意力核和适配器技术，引入新型置信度头来评估对接质量。

Result: IntFold在预测精度上与AlphaFold3相当，并能通过适配器实现多种功能扩展。

Conclusion: IntFold是一个多功能且高效的结构预测工具，为复杂生物分子系统提供了更精确的评估方法。

Abstract: We introduce IntFold, a controllable foundation model for both general and
specialized biomolecular structure prediction. IntFold demonstrates predictive
accuracy comparable to the state-of-the-art AlphaFold3, while utilizing a
superior customized attention kernel. Beyond standard structure prediction,
IntFold can be adapted to predict allosteric states, constrained structures,
and binding affinity through the use of individual adapters. Furthermore, we
introduce a novel confidence head to estimate docking quality, offering a more
nuanced assessment for challenging targets such as antibody-antigen complexes.
Finally, we share insights gained during the training process of this
computationally intensive model.

</details>


### [2] [Downregulation of aquaporin 3 promotes hyperosmolarity-induced apoptosis of nucleus pulposus cells through PI3K/Akt/mTOR pathway suppression](https://arxiv.org/abs/2507.02231)
*Yuan Sang,Huiqing Zhao,Jiajun Wu,Ting Zhang,Wenbin Xu,Hui Yao,Kaihua Liu,Chang Liu,Junbin Zhang,Ping Li,Depeng Wu,Yichun Xu,Jianying Zhang,Gang Hou*

Main category: q-bio.BM

TL;DR: 研究表明，高渗透压通过下调AQP3诱导NPC凋亡，抑制PI3K/AKT/mTOR信号通路，而AQP3过表达可逆转这一过程，为IVDD治疗提供新靶点。


<details>
  <summary>Details</summary>
Motivation: 探究高渗透压下AQP3在NPC凋亡中的作用及其机制，以期为IVDD治疗提供新思路。

Method: 通过体外实验研究高渗透压对AQP3表达的影响，以及AQP3过表达或抑制对PI3K/AKT/mTOR通路和NPC凋亡的作用；并利用IVDD大鼠模型验证AQP3的治疗潜力。

Result: 高渗透压下AQP3减少导致PI3K/AKT/mTOR信号抑制、线粒体功能障碍和ROS积累；AQP3过表达可减轻氧化损伤和凋亡，而抑制AQP3则加剧ECM降解。

Conclusion: AQP3缺乏通过抑制PI3K/AKT/mTOR信号通路促进NPC凋亡，成为IVDD的潜在治疗靶点。

Abstract: Hyperosmolarity is a key contributor to nucleus pulposus cell (NPC) apoptosis
during intervertebral disc degeneration (IVDD). Aquaporin 3 (AQP3), a membrane
channel protein, regulates cellular osmotic balance by transporting water and
osmolytes. Although AQP3 downregulation is associated with disc degeneration,
its role in apoptosis under hyperosmotic conditions remains unclear. Here, we
demonstrate that hyperosmolarity induces AQP3 depletion, suppresses the
PI3K/AKT/mTOR signaling pathway, and promotes mitochondrial dysfunction and ROS
accumulation in NPCs. Lentiviral overexpression of AQP3 restores this pathway,
attenuates oxidative damage, and reduces apoptosis, preserving disc structure
in IVDD rat models. In contrast, pharmacological inhibition of AQP3 exacerbates
ECM catabolism and NP tissue loss. Our findings reveal that AQP3 deficiency
under hyperosmolarity contributes to NPC apoptosis via suppression of
PI3K/AKT/mTOR signaling, potentially creating a pathological cycle of disc
degeneration. These results highlight AQP3 as a promising therapeutic target
for IVDD.

</details>


### [3] [HelixDesign-Antibody: A Scalable Production-Grade Platform for Antibody Design Built on HelixFold3](https://arxiv.org/abs/2507.02345)
*Jie Gao,Jing Hu,Shanzhuo Zhang,Kunrui Zhu,Sheng Qian,Yueyang Huang,Xiaonan Zhang,Xiaomin Fang*

Main category: q-bio.BM

TL;DR: 该论文介绍了一个基于HelixFold3的高通量抗体设计平台HelixDesign-Antibody，用于高效生成和筛选抗体候选序列，验证了其在大规模抗体设计中的有效性。


<details>
  <summary>Details</summary>
Motivation: 传统抗体发现方法耗时耗资源，亟需高效、高通量的解决方案以加速抗体工程。

Method: 利用高精度结构预测模型HelixFold3，结合高性能计算支持，进行大规模抗体序列生成及其与抗原相互作用的评估。

Result: 平台能生成多样且高质量的抗体，验证了通过扩大序列空间探索可提高找到最优结合体的概率。

Conclusion: HelixDesign-Antibody为大规模抗体设计提供了高效、无缝的解决方案，并已在PaddleHelix平台上线。

Abstract: Antibody engineering is essential for developing therapeutics and advancing
biomedical research. Traditional discovery methods often rely on time-consuming
and resource-intensive experimental screening. To enhance and streamline this
process, we introduce a production-grade, high-throughput platform built on
HelixFold3, HelixDesign-Antibody, which utilizes the high-accuracy structure
prediction model, HelixFold3. The platform facilitates the large-scale
generation of antibody candidate sequences and evaluates their interaction with
antigens. Integrated high-performance computing (HPC) support enables
high-throughput screening, addressing challenges such as fragmented toolchains
and high computational demands. Validation on multiple antigens showcases the
platform's ability to generate diverse and high-quality antibodies, confirming
a scaling law where exploring larger sequence spaces increases the likelihood
of identifying optimal binders. This platform provides a seamless, accessible
solution for large-scale antibody design and is available via the antibody
design page of PaddleHelix platform.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [4] [STELLA: Self-Evolving LLM Agent for Biomedical Research](https://arxiv.org/abs/2507.02004)
*Ruofan Jin,Zaixi Zhang,Mengdi Wang,Le Cong*

Main category: cs.AI

TL;DR: STELLA是一种自我进化的AI代理，通过动态更新和自主学习提升能力，优于现有模型。


<details>
  <summary>Details</summary>
Motivation: 生物医学领域的快速增长导致研究分散且超出人类专家能力，现有AI代理工具集静态且手动管理，无法适应和扩展。

Method: STELLA采用多代理架构，包含动态演变的模板库和工具海洋，通过工具创建代理自动发现和集成新工具。

Result: STELLA在多个生物医学基准测试中表现优异，准确率高达63%，较领先模型提升6个百分点。

Conclusion: STELLA是一个能学习和成长的动态AI代理系统，显著加速了生物医学发现的步伐。

Abstract: The rapid growth of biomedical data, tools, and literature has created a
fragmented research landscape that outpaces human expertise. While AI agents
offer a solution, they typically rely on static, manually curated toolsets,
limiting their ability to adapt and scale. Here, we introduce STELLA, a
self-evolving AI agent designed to overcome these limitations. STELLA employs a
multi-agent architecture that autonomously improves its own capabilities
through two core mechanisms: an evolving Template Library for reasoning
strategies and a dynamic Tool Ocean that expands as a Tool Creation Agent
automatically discovers and integrates new bioinformatics tools. This allows
STELLA to learn from experience. We demonstrate that STELLA achieves
state-of-the-art accuracy on a suite of biomedical benchmarks, scoring
approximately 26\% on Humanity's Last Exam: Biomedicine, 54\% on LAB-Bench:
DBQA, and 63\% on LAB-Bench: LitQA, outperforming leading models by up to 6
percentage points. More importantly, we show that its performance
systematically improves with experience; for instance, its accuracy on the
Humanity's Last Exam benchmark almost doubles with increased trials. STELLA
represents a significant advance towards AI Agent systems that can learn and
grow, dynamically scaling their expertise to accelerate the pace of biomedical
discovery.

</details>


### [5] [An AI-native experimental laboratory for autonomous biomolecular engineering](https://arxiv.org/abs/2507.02379)
*Mingyu Wu,Zhaoguo Wang,Jiabin Wang,Zhiyuan Dong,Jingkai Yang,Qingting Li,Tianyu Huang,Lei Zhao,Mingqiang Li,Fei Wang,Chunhai Fan,Haibo Chen*

Main category: cs.AI

TL;DR: AI驱动的自主实验室，专注于复杂生物分子工程实验，实现仪器管理、实验流程优化，并支持多用户请求，匹配人类科学家的实验结果。


<details>
  <summary>Details</summary>
Motivation: 实现自主科学研究，解决传统实验对专家的依赖和资源限制，推动科学服务的规模化。

Method: 基于模型、实验和仪器的协同设计理念，构建AI原生自主实验室平台，支持多目标实验和自动化系统共同演进。

Result: 实验室能自主优化实验性能，达到顶尖科学家的水平，并在多用户场景中显著提高仪器利用率和实验效率。

Conclusion: 该平台为生物材料研究提供了新路径，为科学即服务的大规模实现奠定了基础。

Abstract: Autonomous scientific research, capable of independently conducting complex
experiments and serving non-specialists, represents a long-held aspiration.
Achieving it requires a fundamental paradigm shift driven by artificial
intelligence (AI). While autonomous experimental systems are emerging, they
remain confined to areas featuring singular objectives and well-defined, simple
experimental workflows, such as chemical synthesis and catalysis. We present an
AI-native autonomous laboratory, targeting highly complex scientific
experiments for applications like autonomous biomolecular engineering. This
system autonomously manages instrumentation, formulates experiment-specific
procedures and optimization heuristics, and concurrently serves multiple user
requests. Founded on a co-design philosophy of models, experiments, and
instruments, the platform supports the co-evolution of AI models and the
automation system. This establishes an end-to-end, multi-user autonomous
laboratory that handles complex, multi-objective experiments across diverse
instrumentation. Our autonomous laboratory supports fundamental nucleic acid
functions-including synthesis, transcription, amplification, and sequencing. It
also enables applications in fields such as disease diagnostics, drug
development, and information storage. Without human intervention, it
autonomously optimizes experimental performance to match state-of-the-art
results achieved by human scientists. In multi-user scenarios, the platform
significantly improves instrument utilization and experimental efficiency. This
platform paves the way for advanced biomaterials research to overcome
dependencies on experts and resource barriers, establishing a blueprint for
science-as-a-service at scale.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [6] [Guided Generation for Developable Antibodies](https://arxiv.org/abs/2507.02670)
*Siqi Zhao,Joshua Moller,Porfi Quintero-Cadena,Lood van Niekerk*

Main category: cs.LG

TL;DR: 本文介绍了一种计算框架，通过引导离散扩散模型优化抗体序列，以提高其可开发性，并结合SVDD模块增强生物物理可行性。


<details>
  <summary>Details</summary>
Motivation: 为了提高治疗性抗体的临床效果，需要优化其可开发性，包括制造性、稳定性和安全性。

Method: 使用基于自然抗体序列的引导离散扩散模型，并整合SVDD模块指导采样。

Result: 模型能生成与自然抗体库和现有治疗抗体相似的特征，并在SVDD指导下显著提升可开发性评分。

Conclusion: 结合高通量实验，该框架为同时满足结合和生物物理标准的抗体设计提供支持。

Abstract: Therapeutic antibodies require not only high-affinity target engagement, but
also favorable manufacturability, stability, and safety profiles for clinical
effectiveness. These properties are collectively called `developability'. To
enable a computational framework for optimizing antibody sequences for
favorable developability, we introduce a guided discrete diffusion model
trained on natural paired heavy- and light-chain sequences from the Observed
Antibody Space (OAS) and quantitative developability measurements for 246
clinical-stage antibodies. To steer generation toward biophysically viable
candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module
that biases sampling without compromising naturalness. In unconstrained
sampling, our model reproduces global features of both the natural repertoire
and approved therapeutics, and under SVDD guidance we achieve significant
enrichment in predicted developability scores over unguided baselines. When
combined with high-throughput developability assays, this framework enables an
iterative, ML-driven pipeline for designing antibodies that satisfy binding and
biophysical criteria in tandem.

</details>


### [7] [Hierarchical Multi-Label Contrastive Learning for Protein-Protein Interaction Prediction Across Organisms](https://arxiv.org/abs/2507.02724)
*Shiyi Liu,Buwen Liang,Yuetong Fang,Zixuan Jiang,Renjing Xu*

Main category: cs.LG

TL;DR: HIPPO是一个基于层次对比学习的蛋白质-蛋白质相互作用预测框架，通过多层次生物学表征匹配实现了高性能和跨物种预测能力。


<details>
  <summary>Details</summary>
Motivation: 近年来AI在科学领域的进展表明对比学习在整合异构生物数据模态方面具有潜力，但在蛋白质-蛋白质相互作用预测中，如何有效结合层次化特征和跨物种数据仍具挑战。

Method: 提出HIPPO框架，通过层次对比学习对齐蛋白质序列及其层次属性，结合数据驱动的惩罚机制和功能类别的结构化关系，优化嵌入空间。

Result: 在基准数据集上实现最优性能，尤其在低数据量和跨物种零样本预测中表现出色，揭示了层次特征融合对捕捉保守相互作用决定因子的重要性。

Conclusion: HIPPO为稀疏或多物种不平衡数据下的相互作用预测提供了统一框架，推动了跨物种PPI预测的进展。

Abstract: Recent advances in AI for science have highlighted the power of contrastive
learning in bridging heterogeneous biological data modalities. Building on this
paradigm, we propose HIPPO (HIerarchical Protein-Protein interaction prediction
across Organisms), a hierarchical contrastive framework for protein-protein
interaction(PPI) prediction, where protein sequences and their hierarchical
attributes are aligned through multi-tiered biological representation matching.
The proposed approach incorporates hierarchical contrastive loss functions that
emulate the structured relationship among functional classes of proteins. The
framework adaptively incorporates domain and family knowledge through a
data-driven penalty mechanism, enforcing consistency between the learned
embedding space and the intrinsic hierarchy of protein functions. Experiments
on benchmark datasets demonstrate that HIPPO achieves state-of-the-art
performance, outperforming existing methods and showing robustness in low-data
regimes. Notably, the model demonstrates strong zero-shot transferability to
other species without retraining, enabling reliable PPI prediction and
functional inference even in less characterized or rare organisms where
experimental data are limited. Further analysis reveals that hierarchical
feature fusion is critical for capturing conserved interaction determinants,
such as binding motifs and functional annotations. This work advances
cross-species PPI prediction and provides a unified framework for interaction
prediction in scenarios with sparse or imbalanced multi-species data.

</details>
